Skip to content

Intratumoral Heterogeneity on [18F]PSMA and [18F]FDG PET/CT in Predicting Invasion and Prognosis of Prostate Cancer

Intratumoral Heterogeneity on [18F]PSMA-1007 and [18F]FDG PET/CT in Predicting Invasion and Prognosis of Primary Prostate Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06919159
Enrollment
45
Registered
2025-04-09
Start date
2021-07-01
Completion date
2022-11-30
Last updated
2025-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Positron Emission Tomography (PET), Prostate Cancer (Diagnosis), Prostate-specific Membrane Antigen

Keywords

Fluorine-18-fluorodeoxyglucose, Heterogeneity

Brief summary

The purpose of this study is to analyze heterogeneity of prostate cancer(PCa)based on the head-to-head imaging of prostate-specific membrane antigen (PSMA) and fluorodeoxyglucose (FDG) positron emission tomography computed tomography (PET/CT)

Detailed description

PET/CT examinations were performed on different days using Siemens Biograph MCT PET/CT equipment. All patients were examined on the same scanner. Patients were fasted for more than 6 h before \[18F\]FDG PET/CT examination, blood glucose was controlled below 11.1 mmol/L, \[18F\]FDG injection dose was 3.7 MBq/kg, and \[18F\]FDG PET/CT examination was performed after 60 min rest. \[18F\]PSMA-1007 injection dose was 3.7 MBq/kg, and PET/CT scan was performed 60 min after injection. To avoid interference of prostate lesion detection by active urine in the bladder, patients were asked to urinate or undergo forced diuresis before the start of the examination. The scan was performed from the top of the head to the base of the thighs. Low-dose CT was taken with automatic milliampere-second 120 kV voltage scans with a matrix of 512 × 512 and a thickness of 5 mm, and PET/CT image acquisition was taken from 5-6 beds for 2-3 min each. CT data was used for attenuation correction at the end of the acquisition, reconstructed by the two-iteration method (21 subsets in total), and the True X +TOF algorithm was applied to reconstruct the images. Two nuclear medicine physicians with extensive experience in PET/CT interpretation evaluated the images using the LIFEx software v 7.1.0. Both readers were blinded to both clinical and pathological data

Interventions

DIAGNOSTIC_TESTFDG-PET

Different developing agents

DIAGNOSTIC_TESTPSMA PET/CT scan

Different developing agents

Sponsors

Jiequn Yu
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum

Inclusion criteria

* Untreated patients with PCa confirmed by prostate systemic pathological biopsy * Patients underwent \[18F\]PSMA-1007 and \[18F\]FDG PET/CT and the imaging interval was less than one month.

Exclusion criteria

* Patients received treatment at intervals of two imaging * Imaging was less than 1 week after pathology biopsy

Design outcomes

Primary

MeasureTime frame
The relationship between imaging phenotypes and gleason score (GS)From enrollment to the end of 1 month inspection

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026